The mosaic of autoimmunity: Prediction, autoantibodies, and therapy in autoimmune diseases - 2008

Israel Medical Association Journal

Volumn 10, Issue 1, 2008, Pages 13-19

  Shoenfeld, Yehuda ^a,j   Blank, Miri ^a   Abu Shakra, Mahmud ^b,j   Amital, Howard ^c,j   Barzilai, Ori ^a,j   Berkun, Yackov ^a,j   Bizzaro, Nicola ^d   Gilburd, Boris ^a,j   Zandman Goddard, Gisele ^e,j   Katz, Uriel ^a,j   Krause, Ilan ^f,j   Langevitz, Pnina ^a,j   Mackay, Ian R ^g   Orbach, Hedi ^e   Ram, Maya ^a,j   Sherer, Yaniv ^a,j   Toubi, Elias ^h   Gershwin, Eric M ⁱ  

^a SHEBA MEDICAL CENTER   (Israel)

^b BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^c MEIR MEDICAL CENTER   (Israel)

^d Ospedale Civile   (Italy)

^e WOLFSON MEDICAL CENTER   (Israel)

^f RABIN MEDICAL CENTER   (Israel)

^g MONASH UNIVERSITY   (Australia)

^h BNAI ZION MEDICAL CENTER   (Israel)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j TEL AVIV UNIVERSITY   (Israel)

more..

Author keywords

Autoantibodies; Autoimmunity; Biological therapies; Intravenous immunoglobulin; Prediction; Primary biliary cirrhosis; T regulatory cells

Indexed keywords

ADALIMUMAB; AUTOANTIBODY; BIOLOGICAL MARKER; CARDIOLIPIN ANTIBODY; CENTROMERE ANTIBODY; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; DOUBLE STRANDED DNA ANTIBODY; ETANERCEPT; FUNGUS ANTIBODY; GLATIRAMER; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; INFLIXIMAB; LA ANTIBODY; MITOCHONDRION ANTIBODY; NUCLEOSOME ANTIBODY; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE ANTIBODY; RHEUMATOID FACTOR; RIBONUCLEOPROTEIN ANTIBODY; RO ANTIBODY; SM ANTIBODY; SYNTHETIC PEPTIDE; THYROID PEROXIDASE ANTIBODY; TUMOR NECROSIS FACTOR; IMMUNOLOGIC FACTOR; PEPTIDE FRAGMENT; TUMOR NECROSIS FACTOR ALPHA;

ALLERGIC ENCEPHALOMYELITIS; ANAPHYLAXIS; ANKYLOSING SPONDYLITIS; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY TITER; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; BILIARY CIRRHOSIS; CROHN DISEASE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE MARKER; DISEASE SEVERITY; DRUG DESIGN; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; EARLY DIAGNOSIS; HUMAN; IMMUNOMODULATION; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FAILURE; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPH NODE CELL; LYMPHOCYTE FUNCTION; NONHUMAN; PRIMARY BILIARY CIRRHOSIS; PROGNOSIS; PROTEIN TARGETING; PSORIASIS; PSORIATIC ARTHRITIS; REGULATORY T LYMPHOCYTE; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SCLERODERMA; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; TARGET CELL; THROMBOEMBOLISM; VASCULITIS; BLOOD; DESENSITIZATION; DRUG ANTAGONISM; DRUG EFFECT; IMMUNOLOGY; PHYSIOLOGY; REVIEW;

AUTOANTIBODIES; AUTOIMMUNE DISEASES; AUTOIMMUNITY; DESENSITIZATION, IMMUNOLOGIC; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; LIVER CIRRHOSIS, BILIARY; PEPTIDE FRAGMENTS; T-LYMPHOCYTES, REGULATORY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 41149106388     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Bizzaro N, Tozzoli R, Shoenfeld Y. Are we at a stage to predict autoimmune rheumatic diseases? Arthritis Rheum 2007;56:1736-44.
2. Arbuckle MR, Mc Clain MT, Rubertone MV, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003;349:1526-33.
3. Harel M, Shoenfeld Y. Predicting and preventing autoimmunity, myth or reality? Ann N Y Acad Sci 2006;1069:322-45.
4. Bizzaro N. Autoantibodies as predictors of disease: the clinical and experimental evidence. Autoimmun Rev 2007;6:325-33.
5. Israeli E, Grotto I, Gilburd B, et al. Anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies as predictors of inflammatory bowel disease. Gut 2005;54:1232-6.
6. Shepshelovich D, Shoenfeld Y. Prediction and prevention of autoimmune diseases: additional aspects of the mosaic of autoimmunity. Lupus 2006;15:183-90.
7. Merbl Y, Zucker-Toledano M, Quintana FJ, Cohen IR. Newborn humans manifest autoantibodies to defined self molecules detected by antigen microarray informatics. J Clin Invest 2007;117:712-18.
8. Shoenfeld Y. Common infections, idiotypic dysregulation, autoantibody spread and induction of autoimmune diseases. J Autoimmun 1996;9:235-9.
9. Shoenfeld Y, Toubi E. Protective autoantibodies: role in homeostasis, clinical importance, and therapeutic potential. Arthritis Rheum 2005;52:2599-606.
10. Sherer Y, Gorstein A, Fritzler MJ, Shoenfeld Y. Autoantibody explosion in systemic lupus erythematosus: more than 100 different antibodies found in SLE patients. Semin Arthritis Rheum 2004;34:501-37.
11. Shoenfeld Y, Isenberg DA, Rauch J, Madaio MP, Stollar BD, Schwartz RS. Idiotypic cross-reactions of monoclonal human lupus autoantibodies. J Exp Med 1983;158:718-30.
12. Katzav A, Solodeev I, Brodsky O, et al. Induction of autoimmune depression in mice by anti-ribosomal P antibodies via the limbic system. Arthritis Rheum 2007;56:938-48.
13. Zandman-Goddard G, Chapman J, Shoenfeld Y. Autoantibodies involved in neuropsychiatric SLE and antiphospholipid syndrome. Semin Arthritis Rheum 2007;36:297-315.
14. Atzeni F, Turiel M, Capsoni F, Doria A, Meroni P, Sarzi-Puttini P. Autoimmunity and anti-TNF-alpha agents. Ann N Y Acad Sci 2005;1051:559-69.
15. De Rycke L, Baeten D, Kruithof E, Van den Bosch F, Veys EM, De Keyser F. The effect of TNF alpha blockade on the antinuclear antibody profile in patients with chronic arthritis: biological and clinical implications. Lupus 2005;14:931-7.
16. Aharoni R, Teitelbaum D, Sela M, Arnon R. Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppresses experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA 1997;94:10821-6.
17. Eilat E, Dayan M, Zinger H, Mozes E. The mechanism by which a peptide based on complementarity-determining region-1 of a pathogenic anti-DNA auto-Ab ameliorates experimental systemic lupus erythematosus. Proc Natl Acad Sci USA 2001;98:1148-53.
18. Blank M, Faden D, Tincani A, et al. Immunization with anticardiolipin cofactor (beta-2-glycoprotein I) induces experimental antiphospholipid syndrome in naive mice. J Autoimmun 1994;7:441-55.
19. Gharavi AE, Pierangeli SS, Espinola RG, Liu X, Colden-Stanfield M, Harris EN. Antiphospholipid antibodies induced in mice by immunization with a cytomegalovirus-derived peptide cause thrombosis and activation of endothelial cells in vivo. Arthritis Rheum 2002;46:545-52.
20. Blank M, Shoenfeld Y, Cabilly S, Heldman Y, Fridkin M, Katchalski-Katzir E. Prevention of experimental antiphospholipid syndrome and endothelial cell activation by synthetic peptides. Proc Natl Acad Sci USA 1999;96:5164-8.
21. Blank M, Krause I, Fridkin M, et al. Bacterial induction of autoantibodies to beta2-glycoprotein-I accounts for the infectious etiology of antiphospholipid syndrome. J Clin Invest 2002;109:797-804.
22. Shoenfeld Y, Katz U. IVIg therapy in autoimmunity and related disorders: our experience with a large cohort of patients. Autoimmunity 2005;38:123-37.
23. Le Pottier L, Bendaoud B, Dueymes M, et al. BAFF, a new target for intravenous immunoglobulin in autoimmunity and cancer. J Clin Immunol 2007;27:257-65.
24. Blank M, Anafi L, Zandman-Goddard G, et al. The efficacy of specific IVIG anti-idiotypic antibodies in antiphospholipid syndrome (APS): trophoblast invasiveness and APS animal model. Int Immunol 2007;19:857-65.
25. Sherer Y, Shoenfeld Y. Intravenous immunoglobulin for immunomodulation of systemic lupus erythematosus. Autoimmun Rev 2006;5:153-5.
26. Nacci F, Righi A, Conforti ML, et al. Intravenous immunoglobulins improve the function and ameliorate joint involvement in systemic sclerosis: a pilot study. Ann Rheum Dis 2007;66:977-9.
27. Orbach H, Katz U, Sherer Y, Shoenfeld Y. Intravenous immunoglobulin: adverse effects and safe administration. Clin Rev Allergy Immunol 2005;29:173-84.
28. +T cells in patients with active rheumatoid arthritis is reduced by infliximab. Ann N Y Acad Sci 2005; 1051:506-14.
29. Kessel A, Ammuri H, Peri R, et al. IVIg therapy affects T reg cells by increasing their suppressive function. J Immunol 2007;179:5571-5.
30. Behrens F, Himsel A, Rehart S, et al. Imbalance in distribution of functional, autologous regulatory T cells in rheumatoid arthritis. Ann Rheum Dis 2007;66:1151-6.
31. + regulatory T-cell population and autoantibody levels in pediatric patients with systemic lupus erythematosus. Immunology 2006;117:280-6.
32. Nadkarni S, Mauri C, Ehrenstein MR. Anti-TNF-alpha therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-beta. J Exp Med 2007;204:33-9.
33. Gershwin ME, Mackay IR, Sturgess A, Coppel RL. Identification and specificity of a cDNA encoding the 70 kd mitochondrial antigen recognized in primary biliary cirrhosis. J Immunol 1987;138:3525-31.
34. Lleo A, Invernizzi P, Selmi C, et al. Autophagy: highlighting a novel player in the autoimmunity scenario. J Autoimmun (in press).
35. Padgett K, Selmi C, Kenny T, et al. Phylogenetic and immunological definition of four lipoylated proteins from Novosphingobium aromaticivorans, implications for primary biliary cirrhosis. J Autoimmun 2005;24:209-19.
36. Abbas A, Lohr J, Knoechel B. Balancing autoaggressive and protective T cell responses. J Autoimmun 2007;28:59-61.
37. Bagnasco M, Grassia L, Pesce G. The management of the patient with unexpected autoantibody positivity. Autoimmun Rev 2007; 6:347-53.
38. Foreman AL, Van de Water J, Gougeon ML, Gershwin ME. B cells in autoimmune diseases: insights from analyses of immunoglobulin variable (Ig V) gene usage. Autoimmun Rev 2007;6:387-401.
39. Kong JS, Teuber SS, Gershwin ME. Potential adverse events with biologic response modifiers. Autoimmun Rev 2006;5:471-85
40. Aoki CA, Roifman CM, Lian ZX, et al. IL-2 receptor alpha deficiency and features of primary biliary cirrhosis. J Autoimmun 2006;27:50-3.